How to Reduce Inflammation — and Why It May Lift Depression

About one-third of people with major depressive disorder do not respond adequately to standard antidepressants.[^1] For at least some of them, psychiatrists now believe the reason may be biological in a way serotonin-focused treatments were never designed to address: chronic, low-grade inflammation. Elevated inflammatory markers — C-reactive protein, interleukin-6, tumor necrosis factor-alpha — appear in the blood of a disproportionate share of people with treatment-resistant depression, and experimental anti-inflammatory interventions have, in early trials, reduced depressive symptoms in people whose markers were elevated.[^2]

The finding matters because it reframes what depression sometimes is: not primarily a chemical imbalance in the brain's signaling pathways, but a whole-body state in which the immune system has become chronically activated. The brain is downstream of that activation. Inflammatory cytokines cross the blood-brain barrier, alter neurotransmitter metabolism, blunt the reward circuitry, and produce exactly the fatigue, cognitive slowing, and anhedonia that characterize depressive episodes.[^3] Understanding this pathway opens a different set of levers.

What the evidence supports

Several behavioral and lifestyle factors have measurable effects on systemic inflammatory burden, with enough replication to warrant serious clinical attention.

Sleep. Sleep deprivation raises interleukin-6 and C-reactive protein within days. Conversely, consistent, adequate sleep — seven to nine hours for most adults — is one of the most reliable anti-inflammatory interventions available, at zero pharmacological cost.[^4] For people with depression, sleep hygiene is not a soft recommendation; it is a direct biological target.

Exercise. Moderate aerobic exercise produces a well-documented anti-inflammatory effect through multiple pathways, including the release of interleukin-10 and the reduction of adipose tissue, which is itself a source of inflammatory cytokines. A 2019 meta-analysis found that exercise reduced depressive symptoms with an effect size comparable to antidepressants in mild-to-moderate depression.[^5] The mechanism is partly inflammatory, partly neurogenic (exercise stimulates BDNF, which supports hippocampal volume), and partly behavioral.

Diet. The Mediterranean dietary pattern — high in vegetables, legumes, fish, olive oil, and whole grains; low in processed foods and refined carbohydrates — is associated with lower circulating inflammatory markers across large observational studies. A randomized controlled trial published in BMC Medicine (the SMILES trial) found that a Mediterranean-style dietary intervention reduced depressive symptoms significantly compared to social support alone over 12 weeks.[^6] Dietary change is slow, but it is tractable.

Chronic stress reduction. Psychological stress activates the HPA axis and sustains inflammatory tone through glucocorticoid signaling. Mindfulness-based stress reduction and cognitive behavioral therapy both show downstream reductions in inflammatory markers in clinical populations, not merely subjective improvements in mood.[^7] The psychobiological loop runs in both directions: depression raises inflammation, and inflammation deepens depression. Breaking the loop behaviorally is a legitimate clinical strategy.

Social connection. Social isolation is an independent predictor of elevated inflammatory markers — a finding replicated across multiple longitudinal studies. Cacioppo and Hawkley's work on loneliness showed that perceived social isolation predicted increased expression of pro-inflammatory genes, independent of health behavior confounders.[^8] This means that addressing relational poverty is not merely a quality-of-life concern; it is an anti-inflammatory intervention.

What remains uncertain

The inflammatory hypothesis does not yet have a clean clinical protocol. Researchers do not yet know which anti-inflammatory agents work best for which subtypes of depression, how to reliably identify candidates beyond crude CRP cutoffs, or what the long-term risks of anti-inflammatory pharmacotherapy for depression look like. Several trials of celecoxib and minocycline have shown promise; none have produced practice-changing results at scale.[^9]

This uncertainty argues for caution about waiting for a pharmaceutical solution. The behavioral interventions above — sleep, exercise, diet, stress reduction, social connection — carry low risk, compound across systems, and address inflammatory burden whether or not inflammation turns out to be the primary driver of any given person's depression. They are warranted on general grounds even before the inflammation research is fully settled.

For people navigating depression now

If standard antidepressants have not worked, asking a physician to measure inflammatory markers — CRP, at minimum — is a reasonable next step. It will not yield a diagnosis, but it may indicate whether an inflammatory component is worth targeting. Some psychiatrists are already incorporating this into evaluation.

In the meantime, the evidence most directly accessible to individuals points toward the behavioral stack: prioritize sleep over almost everything else, build moderate aerobic movement into most days, shift dietary pattern gradually toward less processed food and more fish and vegetables, reduce chronic stressors where possible, and invest in relationships. None of these are sufficient for severe depression, and none replace competent clinical care. But they work on the biology that the research is increasingly pointing toward, and they do so now, not while waiting for the next generation of immunological treatments.

Depression is a whole-body illness for at least a meaningful subset of the people who carry it. The practical implication is that the body is also a whole-body site of recovery.

References

[^1]: Al-Harbi, K. S. (2012). Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Preference and Adherence, 6, 369-388. [^2]: Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression. JAMA Psychiatry, 70(1), 31-41. [^3]: Miller, A. H., & Raison, C. L. (2016). The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nature Reviews Immunology, 16(1), 22-34. [^4]: Irwin, M. R., Olmstead, R., & Carroll, J. E. (2016). Sleep disturbance, sleep duration, and inflammation: A systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biological Psychiatry, 80(1), 40-52. [^5]: Kvam, S., Kleppe, C. L., Nordhus, I. H., & Hovland, A. (2016). Exercise as a treatment for depression: A meta-analysis. Journal of Affective Disorders, 202, 67-86. [^6]: Jacka, F. N., O'Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., Castle, D., Dash, S., Mihalopoulos, C., Chatterton, M. L., Brazionis, L., Dean, O. M., Hodge, A. M., & Berk, M. (2017). A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Medicine, 15(1), 23. [^7]: Shields, G. S., Spahr, C. M., & Slavich, G. M. (2020). Psychosocial interventions and immune system function: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry, 77(10), 1031-1043. [^8]: Cacioppo, J. T., & Hawkley, L. C. (2009). Perceived social isolation and cognition. Trends in Cognitive Sciences, 13(10), 447-454. [^9]: Kohler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014). Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry, 71(12), 1381-1391.